At present, zoster-associated pain is still notoriously difficult to treat. It is more strongly associated with certain conditions [8], such as advanced age, female sex, severe prodromal symptoms, severe herpetic pain, associated immune diseases, and herpes in specific areas (trigeminal nerve distribution, especially in the eyes, perineum, and brachial plexus). In this case, there were several co-occurring factors: older age, diabetes, severe pain in the herpetic stage, a history of ankylosing spondylitis, and lesions in the trigeminal distribution area. Therefore, the patient was at high risk for zoster-associated pain.
Analysis of patient course transition
The patient's initial symptom was herpes, with severe pain in the first distribution of the trigeminal nerve. After the V1 pain subsided, the symptoms progressed to severe pain in the V2 distribution area. The pain then migrated to the occipital region of the C2 after RF thermocoagulation of the V2. This disease shift is most likely explained by the theory of overspeed inhibition of the heterotopic excitatory sites of the nerve [9], which states that in the presence of the strongest ectopic excitement, other excitement points are inhibited. When the strongest excitement is eliminated, secondary excitement occurs level by level, until all are eliminated. The shift of disease may also be related to the body's perception of pain. When there is more than one area of pain, the area with the most intense pain gets the most attention. After this area is treated, the areas with a lower pain level are immediately upgraded to the most painful areas. In this case, the dominated areas of the V1, V2, and C2 became the most painful areas in sequence, and thus the patient's clinical symptoms continued to change.
Analysis of the reasons for choosing PMC and its curative effects
PMC as a treatment for trigeminal neuralgia was first reported by Mullan in the 1980s [10]. The technique has been shown to be less invasive and more effective [11] than RF thermocoagulation, causing significantly less postoperative facial numbness [12]. PMC has also been shown to be effective in treating trigeminal neuralgia caused by HZ and multiple sclerosis [13]. Due to the short duration of the disease in this case, we determined that PMC was less damaging to the nerves than RF thermocoagulation, and hence chose it as the first treatment option. However, the pain returned 5 days following PMC, and the clinical analgesic effect was insufficient. This case, combined with our team's previous clinical experience using PMC to treat trigeminal neuralgia, demonstrates that the efficacy of PMC for trigeminal neuralgia secondary to HZ is not exact. It may be that the degree of compression cannot destroy the afferent nerve and cut off the peripheral signal.
Analysis of the possible causes of C2 involvement
The varicella-zoster virus invades the body, lurking in the sensory ganglia. In this case, the virus was latent in the trigeminal nucleus. When immunity is compromised, the virus becomes active [14] and spreads through the trigeminal nucleus to the trigeminal spinal tract. The caudal of the trigeminal spinal tract continues with the posterior horn of the cervical spinal nerve root at the C1 and C2 Levels crossing to form the “trigemino–cervical complex” [15]. Therefore, the abnormal signals of the trigeminal and C2 spinal nerves often appear converged in the interference, and are manifested as paresthesia of the cervical nerve distribution area. This case can confirm the anatomic convergence theory between the trigeminal nucleus and cervical spinal nerve. In line with our team’s previous studies, this case indicates that neuralgia induced by HZ is intermixed with electrical excitation [16]. Based on this theory, the best treatment option is to alleviate the pain from the level of the trigeminal nucleus [17]. However, the risks associated with operation are currently relatively high. As a result, for patients such as the one in this case,who cannot increase their oral dose, the symptomatic treatment of the peripheral branches was used to alleviate the patient's clinical symptoms and severe pain. Electrical stimulation may be more effective for such patients if regulatory electrodes are placed in the medulla oblongata plane near the trigeminal nucleus, and this option will be investigated further in future studies by our team.
Analysis of the feasibility and timing of RF thermocoagulation for zoster-associated pain
It is generally believed that RF thermocoagulation is not to be performed in the acute stage of HZ neuralgia [18], and the recovery of nerve function is mainly promoted by PRF. Nerve RF thermocoagulation treatment can be a consideration for zoster-associated pain when indications are strictly controlled, if other treatments fail, and informed consent is obtained.
In this case, the pain was excruciating, large doses of oral medication were ineffective, and PRF and multiple nerve block treatments were unsuccessful. Despite the continuous elevation of oral drug doses, the NRS score remained 9–10, and breakthrough pain was extremely frequent, which seriously affected the quality of life of the patient and his family members. The patient was suicidal, so after communicating with him, we decided to choose RF thermocoagulation therapy. After this treatment, the pain disappeared and the patient was very satisfied with the outcome. There was no recurrence, painless numbness, impaired muscle strength, or other adverse reactions during the one-month follow-up,and there was no recurrence of pain 7 month later. Therefore, our team believes that on the premise of not affecting motor function, RF thermocoagulation should be decisively chosen to alleviate stubborn pain and severe zoster-associated pain, as in this case.